<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835924</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-16-01</org_study_id>
    <nct_id>NCT02835924</nct_id>
  </id_info>
  <brief_title>Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC</brief_title>
  <acronym>RE-ARRANGE</acronym>
  <official_title>A Randomized Phase 2 Study Comparing Different Dose Approaches of Induction Treatment (First Cycle) of Regorafenib in Metastatic Colorectal Cancer (mCRC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of different&#xD;
      dose-escalation approaches of regorafenib in mCRC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of total administrated dose over the planned dose accomplished in each arm.</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity during the whole treatment.</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity during first two cycles.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 mg/day 3w on/1w off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent (IC) obtained before any study specific procedures. Subjects&#xD;
             must be able to understand and willing to sign a written informed consent.&#xD;
&#xD;
          2. Male or female subjects 18 years of age.&#xD;
&#xD;
          3. Life expectancy of at least 3 months.&#xD;
&#xD;
          4. Histological or cytological documentation of adenocarcinoma of the colon or rectum.&#xD;
             All other histological types are excluded.&#xD;
&#xD;
          5. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion&#xD;
             following RECIST criteria v 1.1.&#xD;
&#xD;
          6. Subjects with metastatic colorectal cancer (Stage IV).&#xD;
&#xD;
          7. Progression during or within 3 months following the last administration of approved&#xD;
             standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, an&#xD;
             anti-VEGF and an anti-EGFR (if RAS WT)&#xD;
&#xD;
          8. Subjects treated with oxaliplatin in an adjuvant setting should have progressed during&#xD;
             or within 6 months of completion of adjuvant therapy&#xD;
&#xD;
          9. Subjects who progress more than 6 months after completion of oxaliplatin containing&#xD;
             adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.&#xD;
             Subjects who have withdrawn from standard treatment due to unacceptable toxicity&#xD;
             warranting discontinuation of treatment and precluding retreatment with the same agent&#xD;
             prior to progression of disease will also be allowed into the study&#xD;
&#xD;
         10. ECOG Performance Status of 0 or 1(within 14 days prior to the initiation of study&#xD;
             treatment)&#xD;
&#xD;
         11. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements:&#xD;
&#xD;
               -  Total bilirubin =1.5 x the upper limit of normal (ULN).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN&#xD;
                  (5 x ULN for subjects with liver involvement of their cancer).&#xD;
&#xD;
               -  Alkaline phosphatase limit = 2.5 x ULN (5 x ULN for subjects with liver and/or&#xD;
                  bone involvement of their cancer).&#xD;
&#xD;
               -  Lipase = 1.5 x the ULN.&#xD;
&#xD;
               -  Serum creatinine 1.5 x the ULN or = 30 mL/min as calculated using the&#xD;
                  Cockcroft-Gault equation.&#xD;
&#xD;
               -  Platelet count &gt;100000/mm3, hemoglobin &gt;9 g/dL, absolute neutrophil count (ANC)&#xD;
                  &gt;1500/mm3.&#xD;
&#xD;
               -  International normalized ratio (INR)/ Partial thromboplastin time (PTT) 1.5 x&#xD;
                  ULN. (Subjects who are therapeutically treated with an agent such as warfarin or&#xD;
                  heparin will be allowed to participate provided that no prior evidence of&#xD;
                  underlying abnormality in coagulation parameters exists. Close monitoring of at&#xD;
                  least weekly evaluations will be performed until INR/PTT is stable based on a&#xD;
                  measurement that is pre-dose as defined by the local standard.&#xD;
&#xD;
               -  Blood transfusion to meet the inclusion criteria will not be allowed.&#xD;
&#xD;
         12. Women of childbearing potential and men must agree to use adequate contraception&#xD;
             before entering the program until at least 8 weeks after the last study drug&#xD;
             administration. The investigator or a designated associate is requested to advise the&#xD;
             subject on how to achieve an adequate birth control. Adequate contraception is defined&#xD;
             in the study as any medically recommended method (or combination of methods) as per&#xD;
             standard of care. Women of childbearing potential must have a blood or urine pregnancy&#xD;
             test performed a maximum of 7 days before start of study treatment, and a negative&#xD;
             result must be documented before start of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with regorafenib.&#xD;
&#xD;
          2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             before start of study drug&#xD;
&#xD;
          3. Pregnant or breast-feeding subjects:&#xD;
&#xD;
          4. Congestive heart failure = New York Heart Association (NYHA) class 2.&#xD;
&#xD;
          5. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3&#xD;
             months).&#xD;
&#xD;
          6. Myocardial infarction less than 6 months before start of study drug.&#xD;
&#xD;
          7. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are&#xD;
             permitted).&#xD;
&#xD;
          8. Uncontrolled hypertension. (Systolic blood pressure &gt; 140 mmHg or diastolic pressure&#xD;
             &gt;90 mmHg despite optimal medical management).&#xD;
&#xD;
          9. Arterial or venous thromboembolism within 6 months prior to randomization.&#xD;
&#xD;
         10. Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade 2&#xD;
             dyspnea).&#xD;
&#xD;
         11. Ongoing infection &gt; Grade 2 CTCAE v. 4.0.&#xD;
&#xD;
         12. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         13. Known history of active hepatitis B or C, or chronic hepatitis B or C requiring&#xD;
             treatment with antiviral therapy.&#xD;
&#xD;
         14. Subjects with seizure disorder requiring medication.&#xD;
&#xD;
         15. History of organ allograft.&#xD;
&#xD;
         16. Subjects with evidence or history of any bleeding diathesis, irrespective of severity.&#xD;
&#xD;
         17. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of&#xD;
             study medication.&#xD;
&#xD;
         18. Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         19. Renal failure requiring hemo-or peritoneal dialysis.&#xD;
&#xD;
         20. Dehydration CTCAE v. 4.0 Grade = 1.&#xD;
&#xD;
         21. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results.&#xD;
&#xD;
         22. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation.&#xD;
&#xD;
         23. Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the subject and his/her compliance in the study.&#xD;
&#xD;
         24. Interstitial lung disease with ongoing signs and symptoms&#xD;
&#xD;
         25. Persistent proteinuria of CTCAE Grade 3 (&gt;3.5g/24 hours).&#xD;
&#xD;
         26. Subjects unable to swallow oral medications.&#xD;
&#xD;
         27. Any malabsorption condition.&#xD;
&#xD;
         28. Unresolved toxicity higher than CTCAE (v. 4.0) &gt; Grade 1 attributed to any prior&#xD;
             therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced&#xD;
             neurotoxicity &gt; Grade 2.&#xD;
&#xD;
         29. Subjects treated with strong CYP3A4 inhibitors or inducers (refer to appendix 8 and to&#xD;
             section 6.3.8. Prohibited concomitant medication).&#xD;
&#xD;
         30. Subjects receiving G-CSF within 3 weeks prior to signing the ICF&#xD;
&#xD;
         31. Concomitant participation or participation within the last 30 days in another clinical&#xD;
             trial&#xD;
&#xD;
         32. Systemic anticancer therapy including cytotoxic therapy, signal transduction&#xD;
             inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 weeks&#xD;
             (or within 6 weeks for mitomycin C) before starting to receive study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillem Argiles</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitary Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep MÂª Tabernero, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitary Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for the Treatment of Digestive Tumors</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regorafenib</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

